Bacteriophage Therapy as an Application for Bacterial Infection in China

Author:

Liang Shuang1,Qi Yanling1,Yu Huabo1,Sun Wuwen12,Raza Sayed Haidar Abbas3ORCID,Alkhorayef Nada4ORCID,Alkhalil Samia S.5ORCID,Salama Essam Eldin Abdelhady6ORCID,Zhang Lei12

Affiliation:

1. College of Animal Science and Technology, Jilin Agricultural University, Changchun 130000, China

2. Borui Technology Co., Ltd., Changchun 130000, China

3. College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China

4. Department of Clinical Laboratory Science, College of Applied Medical Sciences, Al-Quway’iyah, Shaqra University, Riyadh 19257, Saudi Arabia

5. Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Shaqra University, Shaqra 11961, Saudi Arabia

6. Anatomy Department College of Medicine, King Saud University, Riyadh 11495, Saudi Arabia

Abstract

Antibiotic resistance has emerged as a significant issue to be resolved around the world. Bacteriophage (phage), in contrast to antibiotics, can only kill the target bacteria with no adverse effect on the normal bacterial flora. In this review, we described the biological characteristics of phage, and summarized the phage application in China, including in mammals, ovipara, aquatilia, and human clinical treatment. The data showed that phage had a good therapeutic effect on drug-resistant bacteria in veterinary fields, as well as in the clinical treatment of humans. However, we need to take more consideration of the narrow lysis spectrum, the immune response, the issues of storage, and the pharmacokinetics of phages. Due to the particularity of bacteriophage as a bacterial virus, there is no unified standard or regulation for the use of bacteriophage in the world at present, which hinders the application of bacteriophage as a substitute for antibiotic biological products. We aimed to highlight the rapidly advancing field of phage therapy as well as the challenges that China faces in reducing its reliance on antibiotics.

Funder

Jilin Province Science and technology development

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference106 articles.

1. The Prehistory of Antibiotic Resistance;Perry;Cold Spring Harb. Perspect. Med.,2016

2. The prospect for bacteriophage therapy in Western medicine;Merril;Nat. Rev. Drug Discov.,2003

3. Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases;Fortuna;Front. Microbiol.,2016

4. Antibiotic reimbursement in a model delinked from sales: A benchmark-based worldwide approach;Rex;Lancet. Infect. Dis.,2016

5. Waglechner, N., and Wright, G.D. (2017). Antibiotic resistance: It’s bad, but why isn’t it worse?. BMC Biol., 15.

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3